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Abstract
Objective: Antiepileptic drugs (AEDs) are commonly prescribed for epilepsy and bipolar disorder but little is known about
their use in pregnancy. We examined secular trends in AED prescribing in pregnancy and pregnancy as a determinant for
stopping AED prescribing.
Methods: We identified 174,055 pregnancies from The Health Improvement Network UK primary care database. Secular
trends in AED prescribing during pregnancy were examined between 1994 and 2009. We used Cox’s regression analyses to
compare time to discontinuation of AED prescriptions between pregnant and non-pregnant women and to identify
predictors of discontinuation of AEDs in pregnancy.
Results: Prescribing of carbamazepine and sodium valproate have declined since 1994 despite being the most commonly
prescribed AEDs in pregnancy up to 2004. Prescribing of lamotrigine in pregnancy has steadily increased and has been the
most popular AED prescribed in pregnancy since 2004. Pregnant women with epilepsy were twice as likely to stop receiving
AEDs (Hazard Ratio (HR) 2.00, 95% Confidence Interval (CI) 1.62–2.47) when compared to non-pregnant women and for
women with bipolar disorder this was even higher (HR 3.07, 95% CI 2.04–4.62). For pregnant women with epilepsy, those
receiving AEDs less regularly before pregnancy were more likely to stop receiving AEDs in pregnancy.
Conclusions: Lamotrigine has been increasingly prescribed in pregnancy over older AEDs namely carbamazepine and
sodium valproate. Pregnancy is a strong determinant for the discontinuation of AED prescribing particularly for women with
bipolar disorder.
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Introduction
In pregnancy, some older antiepileptic drugs (AEDs) have been
found to increase the risk of major congenital malformations
(MCMs), and in particular, sodium valproate is also associated
with developmental delay [1,2]. The benefit of maintaining AEDs
in pregnancy for most women is to control seizures that can harm
the fetus and mother [3]. Over a third of women with bipolar
disorder are also treated with AEDs, [4] which if untreated in
pregnancy, increases the risk of mood episode relapse and
postpartum psychosis [5–7]. This leaves women taking AEDs
and their healthcare professionals with a dilemma as to whether to
continue taking AEDs in pregnancy.
The 2012 clinical guidelines from the National Institute of
Health and Clinical Excellence (NICE) advised caution on the use
of sodium valproate in pregnancy, but their guidance offers little
other advice on which AEDs are safe to use in pregnancy.
However, they recommend seizure freedom in pregnancy should
be sought amongst women with epilepsy [3]. The British National
Formulary (BNF) also emphasises the benefit of continuation of
therapy in pregnancy, stating that the ‘‘risk of harm to the mother
and fetus from a convulsive seizure outweighs that of continued
therapy’’ [8].
There are limited data on how prescribing of AEDs in pregnant
women has changed over time. Evidence based guidance suggest
that changes to a woman’s treatment regimen should be made in
the planning stages of pregnancy to eliminate the need to stop
abruptly, or to switch AEDs during pregnancy [3]. We examined
secular trends of prescribing common AEDs in pregnancy and
assessed whether pregnancy is a major determinant for the
discontinuation of AED prescribing.
Methods
Study design
We conducted a cohort study of pregnant women taking AEDs
using data from The Health Improvement Network (THIN)
(http://csdmruk.cegedim.com/). This is one of the UK’s largest
PLOS ONE | www.plosone.org 1 December 2012 | Volume 7 | Issue 12 | e52339
primary care databases, containing anonymised records for over
9 million patients in 480 practices and is broadly representative of
the UK population in terms of sex, age, size of practice and
geographic distribution [9]. It records the data collected during
a patient’s visit to their general practitioner (GP), including
medical diagnoses and symptoms (based on the Read code system),
[10] additional health data (such as smoking status, test results and
pregnancy details), prescriptions, referrals to secondary care and
anonymised free text information. Demographic information such
as the patient’s date of birth and sex, and a marker of social
deprivation, the Townsend quintile, [11] derived from 2001
census data, are also included.
THIN was approved for use in scientific research by the
National Health Service South-East Multi-centre Research Ethics
Committee in 2003. This study was further approved by the
Scientific Review Committee in 2011. Individual patient consent
was not required because the data are anonymised at source.
We identified 350,630 pregnancies and randomly selected one
pregnancy per woman therefore including 174,055 pregnancies in
this study. Women were first included if they were pregnant
between 1994 and 2009 and their records met pre-defined
standards for acceptable data recording [12].
Pregnancy was defined by Read codes which indicated a de-
livery. The start of each pregnancy was determined by using the
date of the last menstrual period, gestational age at birth,
information on preterm delivery and associated free text data.
Where this information was not available, the start of pregnancy
was assumed to be 280 days before the delivery date. For the study
of secular trends in prescribing, the women were required to be
registered with the practice throughout their pregnancy and to
have received more than one AED prescription within a three
month period in pregnancy. For the study of discontinuation of
AEDs, women were also required to be registered throughout the
six months before pregnancy in order to identify those who were
prescribed AEDs before pregnancy.
A group of non-pregnant women receiving AEDs was defined
for comparison with pregnant women. This included women who
had never been pregnant as well as women who had had one or
more pregnancies. For the latter group we excluded periods where
they were pregnant and excluded periods from two years before
pregnancy to one year after a delivery. These periods were
designed to exclude the time where planning pregnancy,
pregnancy itself or breastfeeding may have an impact on drug
treatment. One non-pregnant period per woman was chosen at
random. A random index date was assigned in the non-pregnant
period. Non-pregnant women were stratified by indication for
AEDs and randomly selected within five year age bands so that the
age distribution was similar to that of pregnant women. Two for
every one pregnant woman taking AEDs were selected.
A list of encrypted Multilex ID codes relating to the AEDs listed
in Chapter 4.8.1 of the BNF was created to identify AED
prescriptions in THIN [8]. THIN does not automatically link
a patient’s prescriptions with the indication, therefore we used
Read codes to identify women with the main indications for AEDs
(epilepsy, bipolar disorder and depression) and searched for
diagnoses made before the delivery date. Where none of these
diagnoses were found, medical records were interrogated to find
plausible indications. Both drug and Read code lists were reviewed
by a GP (IN).
Data analyses
The percentage of pregnancies where AEDs were prescribed
more than once was calculated by year of delivery.
Analysis of discontinuation of AED prescribing was performed
on three groups – women with epilepsy, women with bipolar
disorder or depression, and women with no or other indication for
AEDs. For inclusion in the study, pregnant women had to be
prescribed AEDs at least once in the three months before the start
of pregnancy and non-pregnant women prescribed at least once in
the three months preceding the index date. Their last consecutive
AED prescription was determined if no other AEDs were
prescribed within the subsequent three months of the previous
prescription. Follow-up was measured from three months before
the pregnancy start date and ended at the earlier of the last
Figure 1. Percentage of pregnancies where AEDs were prescribed.
doi:10.1371/journal.pone.0052339.g001
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prescription date, delivery date if the birth was premature, or two
months before the delivery date if the birth was full-term. For non-
pregnant women, follow-up started three months before the index
date and ended at the earlier of the last prescription date or
280 days after the index date. Cox’s proportional hazards
regression model was used to estimate hazard ratios (HRs)
comparing the time to last prescription between pregnant and
non-pregnant women, stratified by indication for AEDs. The
proportion of women continuing to receive AED prescriptions is
described at 92 days follow-up (i.e. , start of pregnancy) and at
288 days (i.e. , beginning of the third trimester). Amongst the
women with no or other indication for AEDs, it was not possible to
select a similar non-pregnant group of women, thus HRs were not
estimated for this group.
Factors associated with the discontinuation of AED prescribing
in pregnancy were analysed using Cox’s regression amongst
pregnant women with epilepsy and pregnant women with bipolar
disorder or depression. Maternal age was categorised as younger
than 25, 25–34 and 35+ years. Social deprivation was measured
using the Townsend quintile, a postcode based indicator ranging
from 1 for the least deprived to 5 for most deprived areas. The
number of times AEDs were prescribed prior to the initiation of
follow-up, i.e. in the three to six months before pregnancy, was
counted and categorised as 0, 1 or 2+. Co-medication was
measured as the number of different types of drugs prescribed for
treatment of conditions affecting the central nervous system (BNF
Chapter 4), excluding AEDs and was categorised as 0, 1 and 2+.
Amongst women with epilepsy, co-morbidity with bipolar disorder
or depression was also analysed as a risk factor. Univariable
Table 1. Factors associated with discontinuation of AEDs amongst pregnant women.
Pregnant women with epilepsy (N=745) Pregnant women with bipolar disorder (N=54)





CI) p-value N HR (95% CI) p-value
HR (95%
CI) p-value
Age (years) 0.148 0.282 0.031 0.100




5 1.24 (0.48, 3.25) 1.23 (0.39,
3.91)
25–34 440 1 1 33 1 1









No 662 1 1 n/a n/a




Townsend 0.045 0.208 0.154 0.266
1 136 1 1 9 1 1




7 0.68 (0.22, 2.08) 0.74 (0.20,
2.76)




9 1.40 (0.52, 3.77) 1.43 (0.45,
4.51)




12 2.04 (0.83, 5.03) 2.02 (0.75,
5.48)




11 0.78 (0. 29,2.09) 0.85 (0.28,
2.58)




6 1.05 (0.34, 3.23) 1.67 (0.48,
5.83)
Previous AEDs ,0.0001 ,0.0001 0.159 0.381




15 1.92 (0.98, 3.77) 1.52 (0.66,
3.50)




10 1.45 (0.68, 3.07) 0.74 (0.30,
1.79)
2+ 471 1 1 29 1 1
Co-medications 0.389 0.269 0.148
0 583 1 0.385 1 7 2.01 (0.85, 4.78) 2.63 (0.99,
7.03)




18 1.32 (0.69, 2.51) 1.39 (0.71,
2.72)





For all variables, except Townsend, the most common category formed the reference group.
doi:10.1371/journal.pone.0052339.t001
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analyses of each of these factors and adjusted analyses including all
factors in the regression model were performed. Separately, we
also compared discontinuation of AEDs amongst pregnant women
by specific AEDs prescribed in the three months before pregnancy.
Data were analysed using Stata 11.1.
Results
Secular trends in prescribing
Over the late 1990 s, approximately 0.5–0.6% of pregnancies
had an AED prescribed during the course of the pregnancy. Over
the period from 2000 to 2009, the rate fell slightly and varied
between 0.37% in 2003 to 0.54% in 2009 (Figure 1). Up to 2004
carbamazepine was the most commonly prescribed AED in
pregnancy followed by sodium valproate. Prescribing of carbama-
zepine and sodium valproate in pregnancy, however, fell by 70%
from 1994 to 2004. The prescribing of lamotrigine in pregnancy
steadily increased from 2000 onwards and since 2004 has been the
most commonly prescribed AED in pregnancy. By 2009, 0.25% of
pregnant women were prescribed lamotrigine in pregnancy;
carbamazepine was prescribed in 0.15% of pregnancies and
sodium valproate in 0.10%.
Factors associated with discontinuation of AEDs in
pregnancy
Overall, 934 pregnant women received AED prescriptions in
the three months before pregnancy. Of these, 745 women had
a clinical record of epilepsy and 54 of bipolar disorder or
depression.
Women with epilepsy. The majority of the 745 women
prescribed AEDs for epilepsy were aged 25–34 years, were
prescribed AEDs more than once prior to follow-up and were
receiving no other medication (Table 1).
The frequency of AED prescriptions prior to follow-up
significantly impacted upon the time to last AED prescription in
pregnant women with epilepsy (Table 1). Women with no
prescriptions in the three to six months before pregnancy were
six times more likely to have stopped receiving AEDs in pregnancy
than those who had been prescribed on more than one occasion
(HR 6.32, 95% CI 4.57–8.73), whilst women with just one
prescription in the three to six months before pregnancy were
three times more likely to stop receiving treatment in pregnancy
(HR 3.31, 95% CI 2.57–4.23).
Women with bipolar disorder or depression. The
majority of the 54 women who were prescribed AEDs for bipolar
disorder or depression were aged 25–34 years and had been
prescribed AEDs more than once during the three to six months
before pregnancy. Most received two or more concomitant
medications.
None of the examined factors were found to be associated with
the time to last AED prescription amongst pregnant women with
bipolar disorder or depression (Table 1).
Specific AED associations with discontinuation of AEDs in
pregnancy
Figure 2 shows the discontinuation rates for pregnant women
with epilepsy by AED (sodium valproate, carbamazepine, lamo-
trigine). Compared to those receiving sodium valproate, women
prescribed lamotrigine were less likely to stop AEDs in pregnancy
(HR 0.63, 95% CI 0.46–0.86). Amongst pregnant women with
bipolar disorder or depression, data were too few to analyse.
Pregnancy – a determinant for discontinuing AEDs?
Women with epilepsy. In 745 pregnant women with
epilepsy who had received an AED during the three months prior
to pregnancy, 601 (80.7%) also received AEDs during pregnancy
and 369 (62.4%) were prescribed AEDs in their last trimester. In
comparison, of 1490 non-pregnant women with epilepsy, 1240
(83.2%) received AEDs after 92 days and 1073 (72.0%) were
prescribed AEDs after 288 days (Figure 3a). The HR for pregnant
women with epilepsy stopping AEDs during pregnancy compared
to non-pregnant women was 2.00 (95% CI 1.62–2.47).
Women with bipolar disorder or depression. Pregnant
women with bipolar disorder or depression were three times as
likely to discontinue AED prescriptions compared to non-pregnant
women (HR 3.07, 95% CI 2.04–4.62). In pregnancy, only half
were still being prescribed AEDs (N= 27) and only 8 (14.8%) were
Figure 2. Proportion of pregnant women with epilepsy continuing AEDs by AED.
doi:10.1371/journal.pone.0052339.g002
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prescribed AEDs in the last trimester. In comparison, of 108 non-
pregnant women 82 (75.9%) continued to receive AEDs after
92 days and 58 (53.7%) past 288 days (Figure 3b).
We reviewed the prescription records after the date of the last
AED prescription for all 54 women, and found 17 (31%)
continued to be prescribed antidepressants or antipsychotics after
stopping AEDs. However, 27 (50%) stopped altogether (though
some restarted after the first trimester).
Women with other indications for AEDs than epilepsy and
bipolar disorder. In total 135 women were prescribed AEDs
in the three months before pregnancy without an indication of
epilepsy, bipolar disorder or depression. Only 59 (43.7%)
continued receiving AEDs in pregnancy and 19 (14.1%) were
prescribed AEDs in the final trimester. Of the 59 women who
continued prescriptions into pregnancy, 26 had clinical records for
chronic or neuropathic pain, 15 had records relating to treatment
for mental health including depression (diagnoses made more than
a year before pregnancy), anxiety and personality disorders, three
with migraines, two had suspected epilepsy and the remaining 13
indications could not be ascertained from the medical records.
Furthermore, of the 19 women who were still prescribed at the end
of the second trimester, six were treated for mental health
problems, another six for chronic or neuropathic pain, two with
suspected epilepsy, one with migraines and indications for four
women could not be identified.
Discussion
There has been a decline in prescribing of the older AEDs
namely carbamazepine and sodium valproate since 1994 whereas
prescribing of lamotrigine, a newer AED, has increased five-fold
since 2000. Amongst pregnant women with epilepsy, those
receiving prescriptions more often prior to pregnancy were more
likely to continue receiving AED prescriptions during pregnancy.
Furthermore, those receiving lamotrigine were less likely to stop in
pregnancy compared to women prescribed sodium valproate.
Pregnancy was a determinant for the discontinuation of AED
Figure 3. Proportion of women continuing AEDs: pregnant vs. non-pregnant women with A. epilepsy B. bipolar disorder or
depression.
doi:10.1371/journal.pone.0052339.g003
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prescribing, in particular for women with bipolar disorder or
depression. The majority of pregnant women prescribed AEDs for
indications other than epilepsy and bipolar disorders discontinued
prescriptions by six weeks into pregnancy.
The secular changes in prescribing habits observed in this study
were similar to those seen in other countries. A fall in the use of
carbamazepine and sodium valproate and a rise in lamotrigine
were observed in the Australian Register of Antiepileptic Drugs in
Pregnancy, the European and International Registry of Antiepi-
leptic Drugs in Pregnancy and the Neurodevelopmental Effects of
Antiepileptic Drugs study groups [13–15]. Sodium valproate and
carbamazepine have been linked to severe teratogenic effects when
taken in pregnancy [16–22]. Initially their prescription in
pregnancy decreased over time. However, it is noticeable that
since 2004 prescribing of these drugs in pregnancy remained
relatively constant and that by 2009 they were still the second and
third most commonly prescribed AED in pregnancy. The reasons
for increased prescribing of lamotrigine are unclear – no formal
guidance has been issued indicating the safety of lamotrigine.
Recent evidence suggests no greater risk of MCMs is associated
with lamotrigine when compared to untreated pregnancies in
women with epilepsy [20,21]. However, one study does report an
increased risk of isolated cleft palate/lip in lamotrigine exposed
babies compared to the general population and the BNF states
lamotrigine is associated with increased teratogenicity [8,23]. The
guidance from the NICE is inconsistent. It states lamotrigine
should not be prescribed to pregnant women with bipolar disorder
because of the risk of harm to the fetus, but such advice is not
provided in the guidance for women with epilepsy [3,24]. Our
results on secular prescribing trends and discontinuation of specific
AEDs in pregnancy suggest that many healthcare professionals are
selectively prescribing lamotrigine. Further data are required on
the risks and benefits of prescribing lamotrigine in pregnancy.
To our knowledge, no other study has examined the discon-
tinuation of AEDs in pregnancy. Our study showed that pregnant
women were more likely to stop receiving AED treatment
compared to non-pregnant women also receiving AEDs. This
behaviour has been reported for other medications prescribed to
pregnant women as they were concerned about the effect the
drugs would have on the fetus [25,26]. Our data cannot explain
the behaviour, as we are unable to determine if it was the GP, the
woman or both who were choosing to stop AEDs. We can only
observe that women in pregnancy stop AEDs sooner than when
they are not pregnant. Women with epilepsy behaved differently
from those with bipolar disorder or depression. We separated these
two groups since we had observed a similar steep decline in
antidepressant prescribing in pregnancy in a previous study [27].
Pregnant women with epilepsy were twice as likely not to receive
AEDs whilst this was more than three-fold in pregnant women
with bipolar disorder or depression. We found a third of the
women who were prescribed AEDs for bipolar disorders continued
to be prescribed other alternative drugs such as antidepressants
and antipsychotics.
Women with epilepsy who received frequent prescriptions prior
to pregnancy were less likely to stop these drugs in pregnancy.
These women may be those with a more severe form of the disease
which requires regular consultation with their GP. It may also be
that women receiving frequent AED prescriptions are those that
are more likely to adhere to their medication.
We found no significant associations for the discontinuation of
AEDs amongst pregnant women with bipolar disorder but we
were limited by a small sample size.
Stopping medication in pregnancy is a choice that women
should make rather than being forced to continue treatment
against their wishes. The issue is whether women are fully
informed before they make this choice. A recent survey of women
with epilepsy highlighted failures in women receiving appropriate
pre-conception counselling on the risks AEDs pose to the unborn
child, despite the recommendation by NICE for this to be
conducted for all women with epilepsy of childbearing potential
[3,28]. This suggests that women could be making decisions to
stop or continue AED therapy without fully understanding the
risks and benefits of their actions.
Healthcare professionals need to keep up to date with the latest
information on the risks of AEDs in pregnancy [3]. There is lack of
information on the relative risks between AEDs – a common
choice healthcare professionals and women have to make.
Research efforts in this area must therefore continue and must
be more robust in order for stronger inferences to be made and
clearer guidance to be provided.
The main strength of our study is the large sample size of
women taking AEDs. Although this study is restricted to primary
care, it captures the prescribing patterns for women who attend
secondary and tertiary care. Neurologists and psychiatrists most
often initiate this drug treatment, but in the UK the prescribing is
then passed on to GPs who are wholly responsible for long term
prescribing. Therefore the trends observed in this study are
representative of most pregnant women taking AEDs.
The major limitation of the study is the verification of
adherence to prescribed treatment. However, a recent study of
UK prescriptions dispensing showed that over 98% of AEDs
prescribed in general practice were dispensed [29].
We found a shift in the prescribing of AEDs in pregnancy from
older to newer ones, in particular there has been a five-fold
increase in the prescribing of lamotrigine since 1994. Pregnancy
was a strong factor for the cessation of AED prescriptions,
particularly in women with bipolar disorder. There are risks and
benefits associated with the (dis)continuation of AEDs in
pregnancy and it is important these are balanced to allow women
and healthcare professionals to make an informed decision on
whether to continue treatment in pregnancy. Further research is
urgently needed to firmly establish the safety of AEDs in
pregnancy, particularly for the increasingly prescribed AED,
lamotrigine.
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